May 16, 2017 7:00am EDT Can-Fite Files Clinical Trial Application in Canada for Piclidenoson Ahead of Upcoming Acrobat Rheumatoid Arthritis Phase III Study
May 03, 2017 7:00am EDT Can-Fite's Liver Protective Drug Namodenoson Enters Phase II Trial for Treatment of NAFLD/NASH
Apr 25, 2017 7:00am EDT Can-Fite's Phase III ACRobat Trial in Rheumatoid Arthritis Approved by Institutional Review Board
Feb 28, 2017 7:00am EST New Preclinical Data Show Can-Fite's Namodenoson (CF102) Prevents Progression of Liver Fibrosis
Feb 08, 2017 7:00am EST Can-Fite Gears Up for ACRobat, its Phase III Trial of Piclidenoson in Rheumatoid Arthritis
Jan 09, 2017 7:00am EST Can-Fite Receives IRB Approval to Commence Patient Enrollment in Phase II NAFLD/NASH Trial in Q1 2017
Dec 21, 2016 7:00am EST Can-Fite Receives $500,000 Payment as Part of $3 Million Distribution Deal for Liver Cancer Drug Namodenoson (CF102) in South Korea
Dec 16, 2016 7:00am EST New Preclinical Data Show Can-Fite's Namodenoson (CF102) Inhibits Liver Fibrosis -- Supports Potential Efficacy in Treatment of NASH
